Evotec enters into respiratory diseases alliance with IR Pharma


To provide integrated drug discovery solutions to pharma and biotech companies

Evotec has entered into an exclusive alliance with IR Pharma of the UK to provide integrated drug discovery solutions to pharmaceutical and biotech companies in the field of respiratory diseases.

The collaboration expands the Hamburg, Germany based firm’s drug discovery platform into respiratory diseases through IR Pharma’s expertise in in vitro and in vivo respiratory pharmacology.

Evotec says it is now positioned to offer seamless, fully integrated respiratory and inflammation focused drug discovery programmes to its partners, from target to nomination of pre-clinical development candidates.

Evotec’s chief operating officer Dr Mario Polywka, said: ‘This co-operation is a significant addition to our strategy to offer the most comprehensive drug discovery solutions to our partners.’

IR Pharma, based in Sittingbourne, Kent has a range of highly validated models focusing on asthma, cough and chronic obstructive pulmonary disease (COPD), based on the expertise of the Respiratory Pharmacology group at the National Heart and Lung Institute at Imperial College, led by Professor Maria Belvisi and Dr Mark Birrell. This work complements Evotec’s platform, thus enabling a fully integrated approach to drug discovery in this area.

No financial details were disclosed.